Clinical Trial Update: Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial comparing low-dose total skin electron beam therapy with vorinostat versus TSEBT alone in mycosis fungoides was terminated, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: Stanford University | Conditions: Cutaneous Lymphoma, Cutaneous T-cell Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-11-20